ATP-TCA体外药敏检测对NHL临床治疗指导价值的探讨  

ATP-TCA drug sensitivity testing and its implications in recurrent and refractory NHL treatment in vitro

作　　者：杨磊[1] 宋诸臣[1] 徐小红[1] 蒋斌[1] 彭春雷[1] 魏金芝[1] 

机构地区：[1]南通市肿瘤医院内科,江苏南通226361

出　　处：《中华肿瘤防治杂志》2012年第20期1582-1586,共5页Chinese Journal of Cancer Prevention and Treatment

基　　金：南通市科技局指令性课题(S2006039)

摘　　要：目的:采用三磷酸腺苷生物荧光法(ATP-TCA)对复发或难治非霍奇金淋巴瘤(NHL)组织标本进行体外药敏试验,并分析其临床应用价值。方法:将复发或耐药NHL患者随机分为药敏试验治疗组34例、DICE化疗组30例、GDP化疗组53例、EPOCH组15例。应用ATP-TCA技术对复发或耐药NHL患者术后新鲜组织或胸腔积液或腹水标本进行体外药敏试验。结果:NHL标本的药物敏感性具有个体差异性,不同化疗药物的体外抑瘤活性不同。ATP-TCA组总有效率(RR)为82.4%(28/34),完全缓解率(CR)为52.9%(18/34);DICE化疗组RR为60.0%(18/30),CR为33.3%(10/30);GDP化疗组RR为62.3%(33/53),CR为26.4%(14/53);EPOCH化疗组RR为60.0%(9/15),CR为20%(3/15);ATP-TCA组的有效率优于DICE组及GDP组,P值均<0.05。结论:ATP-TCA体外药敏检测结果与临床治疗反应有很好的相关性,是开展肿瘤个体化化疗的一种重要的体外药物筛选方法。OBJECTIVE ： To determine the correlation between the results of ATP bioluminescence tumor chemosen sitivity assay （ATP-TCA）in recurrent and refractory NHL specimens in vitro and the clinical chemotherapeutic responses of patients. METHODS.. Patients were randomly grouped into 4 teams： ATP-TCA, DICE, GDP and EPOCH. Thirty-four freshly taken recurrent and refractory NHL specimens were tested in vitro for cancer chemosensitivity by ATP-TCA. RE- SULTS： The drug sensitivity of NHL specimens had heterogeneity. Different drugs had different tumor growth inhibition ratio in vitro. Cilnical outcome of the patients receiving chemotherapy according to in vitro assay was as follows ： response rate （RR,CR ＋ PR） was 82.4%（28/34） ,complete response rate （CR） was 52.9%（18/34）. While in DICE case response rate was 60.0%（18/30）,complete response rate was 33.3% （10/30）. In GDP case response rate was 62.3% （33/53）, complete response rate was 26.4 % （14/53）. In EPOCH case response rate was 60.0 % （9/15）, complete response rate was 20% （3/15）. In control cases which were significantly poorer than that in test group. CONCLUSION：The results of ATP TCA assay are correlated well with clinical treatment responses. The assay may be an important and useful method for in dividual-based chemotherapy of cancers.

关 键 词：淋巴瘤 非霍奇金 腺苷三磷酸 微生物敏感性试验 药物耐药性 

分 类 号：R733.1[医药卫生—肿瘤]